RDY
Price
$14.83Alerts
Change
-$0.03 (-0.20%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
12.42B
71 days until earnings call
Intraday BUY SELL Signals
TEVA
Price
$43.24Alerts
Change
+$0.84 (+1.98%)
Updated
Nov 11 closing price
Capitalization
49.7B
90 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RDY vs TEVA

RDY vs TEVA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
RDY vs. TEVA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RDY is a Buy and TEVA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for RDY with price predictions
Nov 11, 2026

Momentum Indicator for RDY turns positive, indicating new upward trend

RDY saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 51 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 61%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for RDY just turned positive on October 09, 2026. Looking at past instances where RDY's MACD turned positive, the stock continued to rise in 29 of 48 cases over the following month. The odds of a continued upward trend are 60%.

Following a +3.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDY advanced for three days, in 157 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.

The Aroon Indicator entered an Uptrend today. In 85 of 243 cases where RDY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

RDY broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. RDY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.032) is normal, around the industry mean (6.379). P/E Ratio (0.375) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (1.666) is also within normal values, averaging (2.202). Dividend Yield (0.020) settles around the average of (0.062) among similar stocks. P/S Ratio (2.817) is also within normal values, averaging (183.387).

The Tickeron Profit vs. Risk Rating rating for this company is 62 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 73 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for TEVA with price predictions
Nov 11, 2026

TEVA's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for TEVA turned positive on November 03, 2026. Looking at past instances where TEVA's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 03, 2026. You may want to consider a long position or call options on TEVA as a result. In 53 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

Following a +2.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 229 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

The Aroon Indicator entered an Uptrend today. In 208 of 282 cases where TEVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.

TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.410) is normal, around the industry mean (6.379). P/E Ratio (68.726) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.202). Dividend Yield (0.008) settles around the average of (0.062) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (183.387).

FUNDAMENTALS RATINGS
RDY vs TEVA: Fundamental Ratings
RDY
TEVA
OUTLOOK RATING
1..100
3381
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
77
Overvalued
PROFIT vs RISK RATING
1..100
625
SMR RATING
1..100
7372
PRICE GROWTH RATING
1..100
4039
P/E GROWTH RATING
1..100
977
SEASONALITY SCORE
1..100
5n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RDY's Valuation (50) in the Pharmaceuticals Generic industry is in the same range as TEVA (77). This means that RDY’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (5) in the Pharmaceuticals Generic industry is somewhat better than the same rating for RDY (62). This means that TEVA’s stock grew somewhat faster than RDY’s over the last 12 months.

TEVA's SMR Rating (72) in the Pharmaceuticals Generic industry is in the same range as RDY (73). This means that TEVA’s stock grew similarly to RDY’s over the last 12 months.

TEVA's Price Growth Rating (39) in the Pharmaceuticals Generic industry is in the same range as RDY (40). This means that TEVA’s stock grew similarly to RDY’s over the last 12 months.

TEVA's P/E Growth Rating (7) in the Pharmaceuticals Generic industry is significantly better than the same rating for RDY (97). This means that TEVA’s stock grew significantly faster than RDY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RDYTEVA
RSI
ODDS (%)
Bearish Trend 1 day ago
75%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 1 day ago
60%
Momentum
ODDS (%)
Bullish Trend 1 day ago
61%
Bullish Trend 1 day ago
68%
MACD
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
50%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
45%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 3 days ago
49%
Bullish Trend 3 days ago
76%
Declines
ODDS (%)
Bearish Trend 1 day ago
55%
Bearish Trend 7 days ago
66%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bullish Trend 1 day ago
35%
Bullish Trend 1 day ago
74%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (RDY: $14.86 vs. TEVA: $42.40)
Brand notoriety: RDY: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: RDY: 59% vs. TEVA: 100%
Market capitalization -- RDY: $12.42B vs. TEVA: $49.7B
RDY [@Pharmaceuticals: Generic] is valued at $12.42B. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $49.7B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RDY’s FA Score shows that 0 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).

  • RDY’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 2 green, 3 red.
According to our system of comparison, TEVA is a better buy in the long-term than RDY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RDY’s TA Score shows that 4 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).

  • RDY’s TA Score: 4 bullish, 4 bearish.
  • TEVA’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, TEVA is a better buy in the short-term than RDY.

Price Growth

RDY (@Pharmaceuticals: Generic) experienced а +3.92% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +1.17% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.

Reported Earning Dates

RDY is expected to report earnings on Jan 22, 2027.

TEVA is expected to report earnings on Feb 10, 2027.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.20% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

RDY and

Correlation & Price change

A.I.dvisor tells us that RDY and VTRS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDY and VTRS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RDY
1D Price
Change %
RDY100%
-0.13%
VTRS - RDY
28%
Poorly correlated
+1.01%
TEVA - RDY
28%
Poorly correlated
+1.98%
ALKS - RDY
28%
Poorly correlated
+3.06%
HROW - RDY
26%
Poorly correlated
-3.26%
DERM - RDY
25%
Poorly correlated
+0.45%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
+1.98%
AMRX - TEVA
40%
Loosely correlated
+1.54%
VTRS - TEVA
35%
Loosely correlated
+1.01%
COLL - TEVA
28%
Poorly correlated
+1.39%
ELAN - TEVA
27%
Poorly correlated
-1.05%
TAK - TEVA
26%
Poorly correlated
-0.43%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WAFU1.390.03
+2.57%
Wah Fu Education & Technology Group Ltd.
SWBI15.830.23
+1.47%
Smith & Wesson Brands
ITT215.01-1.36
-0.63%
ITT
PRVA24.04-0.33
-1.35%
Privia Health Group
AMTX1.43-0.15
-9.75%
Aemetis